Mebufotenin is named as an intervention in 3 current clinical trials in our USA and Switzerland registers. 1 is recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Axial Therapeutic Research (1). The most-studied condition is PTSD - Post Traumatic Stress Disorder.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants
NCT07444788 · ClinicalTrials.gov ↗ · 5-methoxy-dimethyltryptamine (5-MeO-DMT)
|
Phase 1 | Recruiting | University Hospital, Basel, Switzerland | Switzerland |
|
Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects
NCT07540494 · ClinicalTrials.gov ↗ · Healthy Adult
|
Phase 1 | Not yet open | GH Research Ireland Limited | USA |
|
Trifecta Research Study
NCT07717866 · ClinicalTrials.gov ↗ · PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury
|
Observational | Active, closed | Axial Therapeutic Research | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Axial Therapeutic Research | 1 |
| GH Research Ireland Limited | 1 |
| University Hospital, Basel, Switzerland | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 0 |
| Clinical trials in Switzerland | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA and Switzerland registers name Mebufotenin (also registered as 5-methoxy-N,N-dimethyltryptamine) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in Switzerland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Axial Therapeutic Research (1), GH Research Ireland Limited (1) and University Hospital, Basel, Switzerland (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mebufotenin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mebufotenin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mebufotenin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.